These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 30217414)

  • 61. The anemia of inflammation/malignancy: mechanisms and management.
    Adamson JW
    Hematology Am Soc Hematol Educ Program; 2008; ():159-65. PubMed ID: 19074075
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Serum levels of hepcidin and interleukin 6 in Parkinson's disease.
    Kwiatek-Majkusiak J; Geremek M; Koziorowski D; Tomasiuk R; Szlufik S; Friedman A
    Acta Neurobiol Exp (Wars); 2020; 80(3):297-304. PubMed ID: 32990287
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The design and synthesis of novel orally active inhibitors of AP-1 and NF-kappaB mediated transcriptional activation. SAR of in vitro and in vivo studies.
    Palanki MS; Erdman PE; Ren M; Suto M; Bennett BL; Manning A; Ransone L; Spooner C; Desai S; Ow A; Totsuka R; Tsao P; Toriumi W
    Bioorg Med Chem Lett; 2003 Nov; 13(22):4077-80. PubMed ID: 14592511
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Sustained plasma hepcidin suppression and iron elevation by Anticalin-derived hepcidin antagonist in cynomolgus monkey.
    Hohlbaum AM; Gille H; Trentmann S; Kolodziejczyk M; Rattenstetter B; Laarakkers CM; Katzmann G; Christian HJ; Andersen N; Allersdorfer A; Olwill SA; Meibohm B; Audoly LP; Swinkels DW; van Swelm RPL
    Br J Pharmacol; 2018 Apr; 175(7):1054-1065. PubMed ID: 29329501
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Oral administration of a bone morphogenetic protein type I receptor inhibitor prevents the development of anemia of inflammation.
    Mayeur C; Kolodziej SA; Wang A; Xu X; Lee A; Yu PB; Shen J; Bloch KD; Bloch DB
    Haematologica; 2015 Feb; 100(2):e68-71. PubMed ID: 25326432
    [No Abstract]   [Full Text] [Related]  

  • 66. Transient decrease of serum iron after acute erythropoietin treatment contributes to hepcidin inhibition by ERFE in mice.
    Artuso I; Pettinato M; Nai A; Pagani A; Sardo U; Billoré B; Lidonnici MR; Bennett C; Mandelli G; Pasricha SR; Ferrari G; Camaschella C; Kautz L; Silvestri L
    Haematologica; 2019 Mar; 104(3):e87-e90. PubMed ID: 30266734
    [No Abstract]   [Full Text] [Related]  

  • 67. Unfractionated heparin reduces hepcidin levels in critically ill patients.
    Vagionas D; Politou M; Kompoti M; Papadakis DD; Kostakou E; Theodoulou D; Kaniaris E; Rovina N; Koutsoukou A; Vasileiadis I
    Intern Med J; 2021 May; 51(5):797-801. PubMed ID: 34047020
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Hypoxia attenuates inflammation-induced hepcidin synthesis during experimental human endotoxemia.
    Kiers D; van Eijk LT; van der Hoeven JG; Swinkels DW; Pickkers P; Kox M
    Haematologica; 2019 Jun; 104(6):e230-e232. PubMed ID: 30655372
    [No Abstract]   [Full Text] [Related]  

  • 69. Anemia of inflammation.
    Roy CN
    Hematology Am Soc Hematol Educ Program; 2010; 2010():276-80. PubMed ID: 21239806
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model.
    Miller WH; Bondinell WE; Cousins RD; Erhard KF; Jakas DR; Keenan RM; Ku TW; Newlander KA; Ross ST; Haltiwanger RC; Bradbeer J; Drake FH; Gowen M; Hoffman SJ; Hwang SM; James IE; Lark MW; Lechowska B; Rieman DJ; Stroup GB; Vasko-Moser JA; Zembryki DL; Azzarano LM; Adams PC; Huffman WF
    Bioorg Med Chem Lett; 1999 Jul; 9(13):1807-12. PubMed ID: 10406646
    [TBL] [Abstract][Full Text] [Related]  

  • 71. DYRK1A and cognition: A lifelong relationship.
    Arbones ML; Thomazeau A; Nakano-Kobayashi A; Hagiwara M; Delabar JM
    Pharmacol Ther; 2019 Feb; 194():199-221. PubMed ID: 30268771
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Development of novel amide-derivatized 2,4-bispyridyl thiophenes as highly potent and selective Dyrk1A inhibitors. Part II: Identification of the cyclopropylamide moiety as a key modification.
    Darwish SS; Abdel-Halim M; ElHady AK; Salah M; Abadi AH; Becker W; Engel M
    Eur J Med Chem; 2018 Oct; 158():270-285. PubMed ID: 30223116
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The Benzoylpiperidine Fragment as a Privileged Structure in Medicinal Chemistry: A Comprehensive Review.
    Bononi G; Lonzi C; Tuccinardi T; Minutolo F; Granchi C
    Molecules; 2024 Apr; 29(9):. PubMed ID: 38731421
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Discovery of DS28120313 as a potent orally active hepcidin production inhibitor: Design and optimization of novel 4,6-disubstituted indazole derivatives.
    Fukuda T; Goto R; Kiho T; Ueda K; Muramatsu S; Hashimoto M; Aki A; Watanabe K; Tanaka N
    Bioorg Med Chem Lett; 2017 Dec; 27(23):5252-5257. PubMed ID: 29079471
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Synthesis and SAR studies of 3,6-disubstituted indazole derivatives as potent hepcidin production inhibitors.
    Fukuda T; Ueda K; Ishiyama T; Goto R; Muramatsu S; Hashimoto M; Watanabe K; Tanaka N
    Bioorg Med Chem Lett; 2017 May; 27(10):2148-2152. PubMed ID: 28377056
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Discovery of DS79182026: A potent orally active hepcidin production inhibitor.
    Fukuda T; Goto R; Kiho T; Ueda K; Muramatsu S; Hashimoto M; Aki A; Watanabe K; Tanaka N
    Bioorg Med Chem Lett; 2017 Aug; 27(16):3716-3722. PubMed ID: 28705644
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Non-Anticoagulant Heparins Are Hepcidin Antagonists for the Treatment of Anemia.
    Poli M; Asperti M; Ruzzenenti P; Naggi A; Arosio P
    Molecules; 2017 Apr; 22(4):. PubMed ID: 28397746
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Added value of hepcidin quantification for the diagnosis and follow-up of anemia-related diseases.
    Lefebvre T; Lasocki S; Fénéant-Thibault M; Lamy PJ; Cunat S; Ropert-Bouchet M; Aguilar-Martinez P; Lehmann S; Delaby C
    Ann Biol Clin (Paris); 2017 Feb; 75(1):9-18. PubMed ID: 28132948
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Discovery of DS42450411 as a potent orally active hepcidin production inhibitor: Design and optimization of novel 4-aminopyrimidine derivatives.
    Fukuda T; Ishiyama T; Katagiri T; Ueda K; Muramatsu S; Hashimoto M; Aki A; Baba D; Watanabe K; Tanaka N
    Bioorg Med Chem Lett; 2018 Nov; 28(20):3333-3337. PubMed ID: 30217414
    [TBL] [Abstract][Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.